NO20062236L - Avendelse av organiske sammensetninger - Google Patents

Avendelse av organiske sammensetninger

Info

Publication number
NO20062236L
NO20062236L NO20062236A NO20062236A NO20062236L NO 20062236 L NO20062236 L NO 20062236L NO 20062236 A NO20062236 A NO 20062236A NO 20062236 A NO20062236 A NO 20062236A NO 20062236 L NO20062236 L NO 20062236L
Authority
NO
Norway
Prior art keywords
disposal
organic compositions
ccb
benazepril
mortality
Prior art date
Application number
NO20062236A
Other languages
English (en)
Inventor
Ken Jamerson
Malcolm Macnab
Bertram Pitt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20062236L publication Critical patent/NO20062236L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Det beskrives en fremgangsmåte for å redusere kardiovaskulær morbiditet og/eller mortalitet omfattende administrering av en kombinasjon omfattende en ACE-inhibitor og en CCB, særlig benazepril og amlodipinbesylat.
NO20062236A 2003-10-20 2006-05-18 Avendelse av organiske sammensetninger NO20062236L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51263403P 2003-10-20 2003-10-20
PCT/EP2004/011824 WO2005037278A2 (en) 2003-10-20 2004-10-19 Tbenazpril and amlodipine for reducing cardiovascular morbidity

Publications (1)

Publication Number Publication Date
NO20062236L true NO20062236L (no) 2006-07-19

Family

ID=34465367

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062236A NO20062236L (no) 2003-10-20 2006-05-18 Avendelse av organiske sammensetninger

Country Status (19)

Country Link
US (2) US20060233876A1 (no)
EP (1) EP1776115A2 (no)
JP (1) JP2007511473A (no)
KR (1) KR20060120126A (no)
CN (1) CN101137367A (no)
AU (1) AU2004281541B2 (no)
BR (1) BRPI0415530A (no)
CA (1) CA2542757A1 (no)
IL (1) IL174927A0 (no)
IS (1) IS8470A (no)
MA (1) MA28108A1 (no)
MX (1) MXPA06004369A (no)
NO (1) NO20062236L (no)
RU (1) RU2006117198A (no)
SG (1) SG147456A1 (no)
TN (1) TNSN06111A1 (no)
TW (1) TW200524591A (no)
WO (1) WO2005037278A2 (no)
ZA (1) ZA200602994B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10127130B2 (en) * 2005-03-18 2018-11-13 Salesforce.Com Identifying contributors that explain differences between a data set and a subset of the data set
US9940405B2 (en) 2011-04-05 2018-04-10 Beyondcore Holdings, Llc Automatically optimizing business process platforms
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
CN102008707B (zh) * 2009-07-14 2012-12-26 邬林祥 一种治疗高血压含喹那普利的复方制剂
WO2011161223A2 (en) 2010-06-23 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
US10802687B2 (en) 2011-12-04 2020-10-13 Salesforce.Com, Inc. Displaying differences between different data sets of a process
US10796232B2 (en) 2011-12-04 2020-10-06 Salesforce.Com, Inc. Explaining differences between predicted outcomes and actual outcomes of a process
CN102440993B (zh) * 2011-12-08 2013-04-17 扬子江药业集团广州海瑞药业有限公司 一种氨氯地平和贝那普利的药物组合物
EP3034071B1 (en) 2011-12-21 2017-12-06 Elanco Tiergesundheit AG New combination
CN102688245A (zh) * 2012-06-11 2012-09-26 北京阜康仁生物制药科技有限公司 一种稳定的氨氯地平与贝那普利药用组合物及其制备方法
JP2014219945A (ja) * 2013-05-10 2014-11-20 富士通株式会社 治験情報出力装置、治験情報出力方法および治験情報出力プログラム
US20200111575A1 (en) * 2018-10-04 2020-04-09 Babylon Partners Limited Producing a multidimensional space data structure to perform survival analysis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162802A (en) * 1992-03-10 2000-12-19 Papa; Joseph Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
IL156136A0 (en) * 2000-12-18 2003-12-23 Novartis Ag Therapeutic combination of amlodipine and benazepril
PE20040468A1 (es) * 2002-05-17 2004-09-14 Novartis Ag Combinacion de compuestos organicos

Also Published As

Publication number Publication date
BRPI0415530A (pt) 2006-12-26
TNSN06111A1 (en) 2007-11-15
WO2005037278A2 (en) 2005-04-28
KR20060120126A (ko) 2006-11-24
ZA200602994B (en) 2008-03-26
CA2542757A1 (en) 2005-04-28
CN101137367A (zh) 2008-03-05
SG147456A1 (en) 2008-11-28
IS8470A (is) 2006-05-16
US20080242659A1 (en) 2008-10-02
JP2007511473A (ja) 2007-05-10
AU2004281541A1 (en) 2005-04-28
MA28108A1 (fr) 2006-08-01
WO2005037278A3 (en) 2007-05-10
US20060233876A1 (en) 2006-10-19
AU2004281541B2 (en) 2008-05-01
EP1776115A2 (en) 2007-04-25
RU2006117198A (ru) 2007-12-10
IL174927A0 (en) 2008-04-13
TW200524591A (en) 2005-08-01
MXPA06004369A (es) 2006-06-14

Similar Documents

Publication Publication Date Title
NO20062236L (no) Avendelse av organiske sammensetninger
DK1507529T3 (da) Kombination indeholdende valsartan, amlodipin og hydrochlorthiazid
NO20031672L (no) Aza- og polyazanaftalenylkarboksamid-derivater anvendbare som HIV-integraseinhibitorer
CY1106044T1 (el) Συνεργατικος αναλγητικος συνδυασμος οπιωδους αναλγητικου και αναστολεα της κυκλοοξυγενασης -2
DE69921358D1 (de) Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
NO955074D0 (no) 1-substituerte istain- og oksindolderivater som inhibitorer til acetylkolinesterase
DK1463716T3 (da) Pyrrolidin- og piperidinderivater som NK1-antagonister
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
IS6828A (is) Nýjar afleiður möndlusýru og notkun þeirra sem þrombínhemla
NO20050652L (no) Pyrrolidone derivater som maob inhibitorer
NO20012229D0 (no) Kombinasjonsbehandling med angiotensin-konverterende enzyminhibitor og aldosteron-antagonist for reduksjon avmorbiditet og mortalitet ved kardiovaskul¶re sykdommer
IL169148A0 (en) Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination
AU2001236605A1 (en) Indole and benzimidazole inhibitors of factor xa
NO20040405L (no) Farmasoytiske sammensetninger av amlodipin og atorvastatin.
TW200508226A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
AR008782A1 (es) Una composicion farmaceutica antitrombotica y antiaterogena, y sus usos
IS6111A (is) Lyfjablanda sem felur í sér þrombínhemil með lágan mólmassa og forlyf hans
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003215756A1 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
TR200000419T2 (tr) Feksofenadin ve türevlerinin biyo elde edilebilirliklerinin arttırılması yöntemi.
GR1004124B (el) Ασπαρτικο παραγωγο της αμλοδιπινης.
DE60108495D1 (en) Thrombin inhibitoren
MXPA03005882A (es) Derivado amida de amlodipina.
DE60031171D1 (de) Ace inhibitor-vasopressin antagonist kombinationen
NO20014191D0 (no) Lås for höy belastning og stor boring

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application